Lung Cancer
Volume 55, Issue 1 , Pages 109-113 , January 2007

Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients

  • Alexander Schmittel

      Affiliations

    • Medizinische Klinik III (Hämatologie, Onkologie und Transfusionsmedizin), Charité Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 30 8445 3090; fax: +49 30 8445 4468.
    • ,
  • Maren Knödler

      Affiliations

    • Medizinische Klinik III (Hämatologie, Onkologie und Transfusionsmedizin), Charité Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    • ,
  • Patricia Hortig

      Affiliations

    • Medizinische Klinik II (Kardiologie und Pulmologie), Charité Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    • ,
  • Karsten Schulze

      Affiliations

    • Medizinische Klinik II (Kardiologie und Pulmologie), Charité Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    • ,
  • Eckhard Thiel

      Affiliations

    • Medizinische Klinik III (Hämatologie, Onkologie und Transfusionsmedizin), Charité Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    • ,
  • Ulrich Keilholz

      Affiliations

    • Medizinische Klinik III (Hämatologie, Onkologie und Transfusionsmedizin), Charité Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany

Received 26 August 2006 ,Revised 24 September 2006 ,Accepted 25 September 2006.

References 

  1. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17:658–667
  2. O’Brien MER, Ciuleanu T, Tsekov H, Shparyk Y, Čučević B, Juhasz G, et al. Survival benefit of oral topotecan plus supportive care versus supportive care alone in relapsed, resistant SCLC. Lung Cancer. 2005;49(2):157
  3. Balfour JA, Goa KL. Bendamustine. Drugs. 2001;61:631–638
  4. Preiss R, Sohr R, Matthias M, Brockmann B, Huller H. The pharmacokinetics of bendamustine (Cytostasane) in humans. Pharmazie. 1985;40:782–784
  5. Diehl V, Cheson BD. Bendamustine in the treatment of hematologic malignancies Introduction.. Semin Oncol. 2002;29:1–3
  6. Schöffski P, Seeland G, Engel H, Grunwald V, Paul H, Merkle K, et al. Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours. Ann Oncol. 2000;11:729–734
  7. Reck M, Haering B, Koschel G, Kaukel E, von Pawel J, Gatzemeier U. Chemotherapy of advanced non-small-cell and small-cell bronchial carcinoma with bendamustine—a phase II study. Pneumologie. 1998;52:570–573
  8. Heider A, Köster W, Grote-Kiehn J, Bremer K, Wilke H, Niederle N. Bendamustin in first-line therapy of extensive disease small cell lung cancer (SCLC): efficacy and toxicity. Onkologie. 1999;22:[abstract 0538]
  9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216
  10. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1–10
  11. Hirose T, Horichi N, Ohmori T, Ogura K, Hosaka T, Ando K, et al. Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer. Lung Cancer. 2003;40:333–338
  12. Mori K, Kamiyama Y, Kondo T, Kano Y, Kodama T. Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small cell lung cancer. Cancer Chemother Pharmacol. 2006;58:86–90
  13. Masters GA, Declerck L, Blanke C, Sandler A, De Vore R, Miller K, et al. Phase II trial of gemcitabine in refractory or relapsed small cell lung cancer: Eastern Cooperative Oncology Group trial 1597. J Clin Oncol. 2003;21:1550–1555

PII: S0169-5002(06)00528-9

doi: 10.1016/j.lungcan.2006.09.029

Lung Cancer
Volume 55, Issue 1 , Pages 109-113 , January 2007

Article Tools

* Image Usage & Resolution